| [1] |
Chen Q, Liu ZC, Cheng LP, et al.An analysis of incidence and mortality of colorectal cancer in China, 2003～2007.China Cancer, 2012, 21(3): 179-182.
|
| [2] |
Ferlay J, Shin HR, Bray F, et al.GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancerbase No.10.Lyon: International Agency for Research on Cancer, 2010.
|
| [3] |
Pinaki R, Dutta, Amit MaityCellular responses to EGFR inhibitors and their relevance to cancer therapy,. Cancer Lett, 2007, 254(2): 165-177.
|
| [4] |
高云，陈嘉昌，朱振宇，等．EGFR基因突变及其检测方法的研究进展．分子诊断与治疗杂志，2011，03(1)，51-57.
|
| [5] |
Wen-Ping Wang, Kang-Ning Wang, Qiang Gaoet al.Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.World Journal of Surgical Oncology, 2012, 10: 14.
|
| [6] |
Dutta PR, Malty A. Cellular responses to EGFR inhibitors and their relevance tocancer therapy.Cancer Letters, 2007, 254(2): 165-177.
|
| [7] |
Ciardiello F, Tortota G. EGFR antagonists in cancer treatment.Negl J Med, 2008, 358(11): 1160-1174.
|
| [8] |
Sharma SV, Bell DW, Settleman J, et al.Epidermal growth factor receptor mutations in lung cancer.Nat Rev Cancer, 2007, 7(3): 169-181.
|
| [9] |
Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer.Apoptosis, 2004, 9(6): 667-676.
|
| [10] |
Edwards LA, Thiessen B, Dragowska WH, et a1.Inhibition of ILK in PTEN-mutant human glioblastonmas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.Oncogene, 2005, 24(22): 3596-3605.
|
| [11] |
Sale EM, Hodgkinson CP, Jones NP, et a1.A new strategy for studyingprotein kinase B and its threeisofornl8: role of protein kinase B inphosphorylating glycogen synthasekinaae-3, tuberin, WNKI, and ATP citrate lyase.Biochemistry, 2006, 45(1): 213-223.
|
| [12] |
Song G, Ouyang GL, Bao SD.The activation of Akt/PKB signaling pathway and cell survival.J Cell Mol Med, 2005, 9(1): 59-71.
|
| [13] |
Huang SM, Bock JM, Harari PM.Epidermal growth factor receptor blockade With C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.Cancer Res, 1999, 59: 1935-1940.
|
| [14] |
McCawley LJ, Brien P, Hudson LG.Over expression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell lines.Endocrinology, 1997, 138: 121-127.
|
| [15] |
Hilda W, Thomas YTargetedtherapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine？. The Oncologist, 2012, 17: 346-358.
|
| [16] |
Esther UC, Sara G, Ellis YI, et al.Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy.Cancers, 2013, 5: 64-91.
|
| [17] |
Nowak P, Cole DC, Brooijmans N, et al.Discovery of potent and selective inhibitors of the mammalian target of rapamycin(mTOR)kinase.J Med Chem, 2009, 52(22): 7081-7089.
|
| [18] |
Ekstrand AI, Jonsson M, Lindblom A, et al.Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.Fam Cancer, 2010, 9(2): 125-129.
|
| [19] |
Abubaker J, Bavi P, Al-Harbi S, et al.Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.Oncogene, 2008, 27(25): 3539-3545.
|
| [20] |
Zhang YH, Wei W, Xu H, et al.Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.Chin Med J(Engl), 2007, 120(9): 743-748.
|
| [21] |
Greijer AE, Diemen PMDV, Fijneman RJA, et al.Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum.Virchows Archiv, 2008, 452(5): 535-544.
|
| [22] |
郝志楠，郑勇斌，肖高春，等．PI3K/AKT及MEK/ERK信号通路抑制剂对结直肠癌血管内皮细胞管道形成的作用．中国医药导报，2014，(23): 30-35.
|
| [23] |
Yamamoto H, Noura S, Okami J, et al.Overexpression of MT1-MMP is insufficient to increase experimental liver metastasis of human colon cancer cells.Int J Mol Med, 2008, 22(6): 757-761.
|
| [24] |
Stahtea XN, Roussidis AE, Kanakis I, et al.Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.Int J Cancer, 2007, 121(12): 2808-2814.
|
| [25] |
Liao CH, Sang S, Ho CT, et al.Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells.J Cell Biochem, 2005, 96(1): 155-169.
|
| [26] |
Iwasaki M, Hinotsu S, Katsura J. Clinical trials and approval of anti-cancer agents.Jpn J ClinOncol, 2010, 40(1): 65-69.
|
| [27] |
Chan JA, Blaszkowsky LS, Enzinger PC, et al.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.Ann Oncol, 2011, 22(6): 1367-1373.
|
| [28] |
Lordick F, Luber B, Lorenzen S, et al.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgem einschaft Internistische Onkologie(AIO). Br J Cancer, 2010, 102(3): 500-505.
|
| [29] |
Okudela K, HaVashi H, Ito T, et al.K-ras gene mutation enhances motilitv of immortalized airway cells and lung adenocarcinoma ceus via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.Am J pathol, 2004；164: 91-100.
|
| [30] |
Konings IR, Verweij J, Wiemer EA, et al.The applicability of mTOR inhibition in solid tumors.Curr Cancer Drug Targets, 2009, 9(3): 439-450.
|
| [31] |
Wolpin BM, Ng K, Zhu AX, et al.Multicenter Phase II Study of Tivozanib(AV-951)and Everolimus(RAD001)for Patients With Refractory, metastatic colorectal cancer.Oncologist, 2013, 18(4): 377-378.
|
| [32] |
Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy.BioDrugs, 2009, 23(2): 77-91.
|
| [33] |
Manegold PC, Paringer C, Kulka U, et al.Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001(Everolimus)increases radiosensitivity in solid cancer.Clin Cancer Res, 2008, 4(3): 892-900.
|